Consensus Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.12 ^USD	-0.22%		-2.36%	-18.86%

Apr. 12	Sector Update: Health Care Stocks Lower Friday Afternoon	MT
Apr. 12	Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	MT

Evolution of the average Target Price on Theravance Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

403acdba038a43f8230d.U5JvsqpoWwbg2f3xYq_QftqztOBGuBI_TVDhb-PAOHo.EsorgdwdbW-2jbypI96GGJTA5ogM6T8OBjqUF4rxSUgfpQj6xSUjfKezsA~91d2bc8de63851877b5a0a707ff18cf1

Analyst Recommendations on Theravance Biopharma, Inc.

Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	Apr. 12	MT
BTIG Starts Theravance Biopharma With Buy Rating, $21 Price Target	Apr. 12	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating	23-05-09	MT
SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating	22-11-17	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating	22-11-08	MT
Theravance Biopharma Rises After SVB Securities Initiates Outperform Rating	22-05-23	MT
SVB Securities Initiates Theravance Biopharma at Outperform With $12 Price Target	22-05-23	MT
HC Wainwright Adjusts Theravance Biopharma's Price Target to $12 From $8, Reiterates Buy Rating	22-02-24	MT
JPMorgan Upgrades Theravance Biopharma to Neutral From Underweight, Lifts Price Target to $12 From $7	21-11-05	MT
THERAVANCE BIOPHARMA : Needham Downgrades Theravance Biopharma to Hold From Buy	21-09-16	MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating	21-09-16	MT
THERAVANCE BIOPHARMA : Morgan Stanley Adjusts Theravance Biopharma's Price Target to $10 from $14, Keeps Underweight Rating	21-09-16	MT
THERAVANCE BIOPHARMA : SVB Leerink Cuts Price Target on Theravance Biopharma to $10 From $29, Keeps Outperform Rating	21-09-16	MT
THERAVANCE BIOPHARMA : HC Wainwright Slashes Price Target on Theravance Biopharma to $8 From $21, Keeps Buy Rating	21-09-16	MT
ANALYST RECOMMENDATIONS : Activision Blizzard, Beyond Meat, Britvic, Las Vegas Sans, Unilever...	21-09-16
THERAVANCE BIOPHARMA : JPMorgan Downgrades Theravance Biopharma to Underweight From Overweight, Adjusts Price Target to $7 From $17	21-09-15	MT
ANALYST RECOMMENDATONS : Asos, Beazley, Factset, Hiscox, Next...	21-08-25
THERAVANCE BIOPHARMA : Morgan Stanley Downgrades Theravance Biopharma to Underweight From Overweight, Lowers PT to $14 From $27	21-08-24	MT
THERAVANCE BIOPHARMA : Evercore ISI Adjusts Theravance Biopharma PT to $21 From $30, Maintains Outperform Rating	21-08-24	MT
THERAVANCE BIOPHARMA : JPMorgan Adjusts Theravance Biopharma's Price Target to $23 From $27, Maintains Overweight Rating	21-08-24	MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma's Price Target to $10 From $20, Maintains Neutral Rating	21-08-24	MT
Today on Wall Street: A new central bank theory	21-08-24
THERAVANCE BIOPHARMA : SVB Leerink Adjusts Price Target on Theravance Biopharma to $29 From $37, Maintains Outperform Rating	21-08-24	MT
THERAVANCE BIOPHARMA : Needham Adjusts Theravance Biopharma's Price Target to $18 From $32, Keeps Buy Rating	21-08-24	MT
THERAVANCE BIOPHARMA : HC Wainwright Adjusts Theravance Biopharma's Price Target to $21 From $32, Maintains Buy Rating	21-08-24	MT